Table 1.
Demographics and clinical characteristics of participants
| Parameter | Training cohort | Validation cohort | Changhai prospective cohort | Zhongda prospective cohort | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Benign+nsPCa | csPCa | p value# | Benign+nsPCa | csPCa | p value# | Benign+nsPCa | csPCa | p value# | Benign+nsPCa | csPCa | p value# | |
| No. pts (%) | 2409 (74.6%) | 821 (25.4%) | 603 (74.6%) | 205 (25.4%) | 274 (60.9%) | 176 (39.1%) | 162 (62.5%) | 97 (37.5%) | ||||
| Age (media, IQR) | 67.00 (61.00–73.00) | 70.00 (64.00–76.00) | <0.001 | 67.00 (61.00–73.00) | 72.00 (67.00–76.00) | <0.001 | 66.00 (61.00–71.00) | 69.50 (64.00–75.00) | <0.001 | 69.00 (63.00–75.00) | 70.00 (66.00–76.00) | 0.053 |
| PSA (media, IQR) | 9.27 (6.78–12.80) | 10.80 (7.73–14.51) | <0.001 | 9.68 (7.12–12.76) | 11.64 (8.41–15.29) | <0.001 | 7.81 (5.91–11.29) | 9.50 (6.91–12.88) | 0.002 | 8.06 (5.97–12.06) | 9.89 (7.14–12.80) | 0.07 |
| B_AREA (media, IQR) | 22.79 (17.94–28.60) | 17.16 (13.95–21.00) | <0.001 | 22.95 (17.76–29.69) | 16.72 (13.76–20.67) | <0.001 | 23.04 (18.64–28.56) | 17.15 (14.40–23.01) | <0.001 | 23.77 (19.46–29.68) | 17.19 (14.06–20.91) | <0.001 |
| fPSA/PSA (media, IQR) | 0.16 (0.11–0.21) | 0.11 (0.08–0.16) | <0.001 | 0.16 (0.11–0.21) | 0.11 (0.08–0.15) | <0.001 | 0.18 (0.13–0.23) | 0.13 (0.09–0.17) | <0.001 | 0.17 (0.13–0.21) | 0.12 (0.09–0.15) | <0.001 |
nsPCa Non-significant prostate cancer, csPCa Clinical significant prostate cancer, IQR Interquartile range, PSA Prostate-specific antigen, tPSA Total PSA, B_AREA Size of B-ultrasound cross-section prostate area
# Mann-Whitney U test